142D6

Key Product Details

Product Description

142D6 is a potent pan-IAP inhibitor (IC₅₀ values are 21, 21 and 43 nM for cIAP1, cIAP2 and XIAP respectively). 142D6 covalently targets Lys residues in the BIR3 domain of the inhibitor of the apoptosis protein (IAP) family. In vitro, 142D6 reduces viability of cultured breast cancer MDA-MB-231 cells (EC₅₀ values are 44 and 61 nM in cell viability and apoptosis assays, respectively). 142D6 is chemically stable in buffer and plasma and is orally bioavailable.

Licensing Information

Sold under patent license from The Regents of the University of California

Product Specifications for 142D6

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for 142D6

The following data is based on the product molecular weight 552.66.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.81 mL	9.05 mL	18.09 mL
5 mM	0.36 mL	1.81 mL	3.62 mL
10 mM	0.18 mL	0.90 mL	1.81 mL
50 mM	0.04 mL	0.18 mL	0.36 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Udompholkul Characterization of a potent and orally bioavailable Lys-covalent inhibitor of apoptosis protein (IAP) antagonist. J.Med.Chem. 2023 PMID: 37262387
• Baggio Aryl-fluorosulfate-based lysine covalent pan-inhibitors of apoptosis protein (IAP) antagonists with cellular efficacy. J.Med.Chem. 2019 PMID: 31550155

Product Documents for 142D6